JP6882450B2 - 脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物 - Google Patents
脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物 Download PDFInfo
- Publication number
- JP6882450B2 JP6882450B2 JP2019506115A JP2019506115A JP6882450B2 JP 6882450 B2 JP6882450 B2 JP 6882450B2 JP 2019506115 A JP2019506115 A JP 2019506115A JP 2019506115 A JP2019506115 A JP 2019506115A JP 6882450 B2 JP6882450 B2 JP 6882450B2
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- pulmonary fibrosis
- exosomes
- adipose
- derived stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims description 162
- 210000000130 stem cell Anatomy 0.000 title claims description 156
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims description 84
- 230000002265 prevention Effects 0.000 title claims description 19
- 239000004480 active ingredient Substances 0.000 title claims description 16
- 239000000203 mixture Substances 0.000 title description 10
- 206010021143 Hypoxia Diseases 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 33
- 239000001301 oxygen Substances 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 230000001146 hypoxic effect Effects 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 15
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 15
- 108090000174 Interleukin-10 Proteins 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229940076144 interleukin-10 Drugs 0.000 claims description 6
- 102100039068 Interleukin-10 Human genes 0.000 claims 1
- 210000004072 lung Anatomy 0.000 description 29
- 238000000034 method Methods 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 19
- 230000007954 hypoxia Effects 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 16
- 206010016654 Fibrosis Diseases 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 230000004761 fibrosis Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 108010006654 Bleomycin Proteins 0.000 description 14
- 229960001561 bleomycin Drugs 0.000 description 14
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 14
- 239000003102 growth factor Substances 0.000 description 14
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 13
- 102000003814 Interleukin-10 Human genes 0.000 description 12
- 230000007959 normoxia Effects 0.000 description 12
- 210000003954 umbilical cord Anatomy 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 238000010253 intravenous injection Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 239000011148 porous material Substances 0.000 description 11
- 208000029523 Interstitial Lung disease Diseases 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 6
- 238000009295 crossflow filtration Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000013028 medium composition Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- -1 cobalt (II) chloride hexahydrate (Cobalt) Chemical compound 0.000 description 3
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 3
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 3
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940068911 chloride hexahydrate Drugs 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- BNJOZDZCRHCODO-UHFFFAOYSA-N dimethyloxalylglycine Chemical compound COC(=O)CNC(=O)C(=O)OC BNJOZDZCRHCODO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010067472 Organising pneumonia Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000017258 Respiratory bronchiolitis-interstitial lung disease syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000025247 virus-associated trichodysplasia spinulosa Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
以下、本発明を具体的に説明する。
本発明の幹細胞は、自己または同種由来の幹細胞であり得、ヒト及び非ヒト哺乳類を含む任意の類型の動物由来であり得る。
1)幹細胞を通常の培養培地に培養した後、無血清及び無抗生剤の培地で継代培養する段階;
2)前記細胞培養上澄液を回収する段階;
3)前記回収した細胞培養上澄液を遠心分離して細胞残余物を除去する段階;
4)前記細胞残余物が除去された細胞培養上澄液を、多重フィルターシステムを介してろ過して分離・精製したエキソソームを得る段階。
具体的に、前記段階1)の幹細胞は、これに制限されないが、脂肪由来幹細胞、臍帯由来幹細胞または骨髓由来幹細胞であり得、例えば、脂肪由来幹細胞であり得る。
前記脂肪由来幹細胞は、人体または動物由来の幹細胞であり得る。
前記段階1)において、幹細胞は、これに制限されないが、正常酸素条件(normoxia condition)または低酸素条件(hypoxic condition)下で培養され得る。
具体的に、10%FBS(fetal bovine serum)及び 1%ペニシリン/ストレプトマイシン(penicillin/streptomycin)が含まれているDMEM(Dulbecco Modified Eagle Medium high glucose)培地であり得る。また、これに制限されないが、血清(serum)、抗生剤(antibiotics)及びフェノールレッド(phenol red)が添加されていないDMEM培地であり得る。
前記段階2)で回収した細胞培養上澄液には、細胞残余物及び幹細胞から分泌したエキソソームが含まれており、前記段階3)で遠心分離することで細胞培養上澄液に含まれている細胞残余物を除去することができる。
前記遠心分離は、これに制限されないが、250〜500xgで5〜10分間行ってもよく、または300xgで10分間行ってもよい。
本発明の一実施例において、培養したヒト脂肪由来幹細胞から回収した細胞培養上澄液を、300xgで10分間遠心分離して細胞残余物(cell debris)を除去し、0.4μmのポアサイズを有するセルストレーナーを用いてポアサイズ以上の残余物を除去し、その後、0.22μmのポアサイズを有するフィルターを用いてポアサイズ以上の細胞残余物を除去した。細胞残余物の除去後に回収した溶液を、4mL/分(min)の流速を加え、500kD MWCOを有するフィルターを用いたタンジェンシャルフローろ過(tangential flow filtration,TFF)過程を通じてタンパク質を除去し、TFF過程後に回収した溶液をソニケーション(sonication)し、前記TFF過程を連続反復して最終的にエキソソームを分離・精製して得た(図2)。
前記注射剤は、リン酸緩衝生理食塩水(phosphate−buffered saline,PBS)をさらに含み得る。即ち、前記注射剤は、リン酸緩衝生理食塩水に脂肪由来幹細胞から抽出されたエキソソームを担持して用いることができる。
前記注射剤は、リン酸緩衝生理食塩水の代わりにハイドロゲルを含み得る。
前記ハイドロゲルは、ヒアルロン酸、ゼラチン、アルジネート、キトサン、フィブリン、エラスチン、コラーゲン及びメチルセルロースから構成された群より選択されたいずれか一つ以上であり得、具体的にヒアルロン酸ハイドロゲルであり得るが、これに限定されない。
幹細胞(stem cell)は、由来した組織及び培養条件によって異なる特性を示し、これによって、相異なる特性を示す幹細胞から抽出されたエキソソームも、内部構成成分に差異を有する(Extracellular vesicles: Exosomes, microvesicles, and friends; G Raposo et al., J. Cell Biol., 2013, Vol.200, No.4, p.373〜383)。即ち、エキソソームを抽出する細胞の種類は、そのエキソソームの特性を決定する非常に重要な要素となる。
前記実施例1から得た多様な由来の幹細胞から抽出された各々のエキソソームの特性を分析した。
多くの臓器は、組織損傷後、炎症と治癒過程を経るようになり、損傷の小さな場合は正常の構造及び機能を維持するが、継続的な損傷があれば、治癒過程で組織が線維化(fibrosis)するようになる。この線維化過程は、コラーゲン、フィブロネクチン(fibronectin)などの細胞外基質(extracellular matrix,ECM)が組織に蓄積されることで正常構造を破壊して機能の障害をもたらす(Tuberculosis and Respiratory Diseases,Vol.54,No.2,p.1−12,Feb,2003)。
幹細胞を用いた通常の実験は、常に正常酸素分圧(酸素21%)下で行われる。しかし、in vivo環境、即ち、幹細胞が実際に身体内で作用するときは、酸素分圧が非常に低いと知られている(Exp Hematol.,2002;30:67−73)。
前記実施例4から得たエキソソーム、即ち、正常酸素条件下で培養された脂肪由来幹細胞から得たエキソソーム(Normoxia−Exo)及び低酸素条件下で培養された脂肪由来幹細胞から得たエキソソーム(Hypoxia−Exo)の肺線維症の治療効果を確認するために、肺線維症の動物モデルを構築し、構築した肺線維症の動物モデルに前記エキソソームを投与することで肺線維症の治療効能を評価した。
Claims (9)
- 脂肪由来幹細胞からエキソソームを得る段階と、前記得られたエキソソームを有効成分として含有させる段階と、含むことを特徴とする肺線維症の予防または治療用の薬学的組成物の製造方法。
- 前記エキソソームが、正常酸素条件下で培養された脂肪由来幹細胞から抽出されたものであることを特徴とする請求項1に記載の肺線維症の予防または治療用の薬学的組成物の製造方法。
- 前記エキソソームが、低酸素条件下で培養された脂肪由来幹細胞から抽出されたものであることを特徴とする請求項1に記載の肺線維症の予防または治療用の薬学的組成物の製造方法。
- 前記低酸素条件は、0.5〜10%の酸素または低酸素細胞感作剤によって誘導されることを特徴とする請求項3に記載の肺線維症の予防または治療用の薬学的組成物の製造方法。
- 脂肪由来幹細胞から由来のエキソソームを有効成分として含むことを特徴とする肺線維症の予防または治療用の薬学的組成物。
- 前記エキソソームが、肝細胞成長因子(HGF)及びインターロイキン−10を含んでいることを特徴とする請求項5に記載の肺線維症の予防または治療用の薬学的組成物。
- 前記薬学的組成物が、気管内投与または吸入投与用であることを特徴とする請求項5に記載の肺線維症の予防または治療用の薬学的組成物。
- 前記薬学的組成物が、注射剤であることを特徴とする請求項5に記載の肺線維症の予防または治療用の薬学的組成物。
- 前記注射剤は、エキソソームが5×108パーチクル/kg〜5×1010パーチクル/kgの濃度で含まれるものであることを特徴とする請求項8に記載の肺線維症の予防または治療用の薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160099778 | 2016-08-05 | ||
KR10-2016-0099778 | 2016-08-05 | ||
PCT/KR2017/008383 WO2018026203A1 (ko) | 2016-08-05 | 2017-08-03 | 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019527702A JP2019527702A (ja) | 2019-10-03 |
JP6882450B2 true JP6882450B2 (ja) | 2021-06-02 |
Family
ID=61073066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019506115A Active JP6882450B2 (ja) | 2016-08-05 | 2017-08-03 | 脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210283183A1 (ja) |
EP (1) | EP3494977A4 (ja) |
JP (1) | JP6882450B2 (ja) |
KR (1) | KR101830290B1 (ja) |
CN (1) | CN109562129B (ja) |
WO (1) | WO2018026203A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180057546A (ko) * | 2016-11-21 | 2018-05-30 | 성균관대학교산학협력단 | 지방줄기세포유래 엑소좀을 유효성분으로 포함하는 간 섬유증 예방 또는 치료용 조성물 |
KR20200142045A (ko) * | 2018-04-10 | 2020-12-21 | 브레인스톰 셀 세라퓨틱스 리미티드 | 세포 타입 특이적인 엑소좀 및 그 용도 |
KR102125567B1 (ko) * | 2019-07-02 | 2020-06-22 | 한양대학교 에리카산학협력단 | 식물 엑소좀의 대량 생산 방법 |
KR102159914B1 (ko) * | 2019-07-30 | 2020-09-24 | 주식회사 엑소코바이오 | 새로운 엑소좀의 생산방법 및 이의 응용 |
JP2022542953A (ja) * | 2019-07-31 | 2022-10-07 | 上▲海▼▲聖▼特佳健康科技▲発▼展有限公司 | 線維化、炎症、及び/又は老化疾患に対する治療薬 |
CN110564682B (zh) * | 2019-09-30 | 2021-04-02 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种大规模生产人脂肪间充质干细胞外泌体的方法 |
CN111363720A (zh) * | 2020-03-28 | 2020-07-03 | 海门生原干细胞科技有限公司 | 一种治疗脑缺血的骨髓间充质干细胞及其制备方法和应用 |
KR102193175B1 (ko) * | 2020-04-07 | 2020-12-18 | 주식회사 엑소스템텍 | 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도 |
KR20210130578A (ko) | 2020-04-22 | 2021-11-01 | 주식회사 아바테라퓨틱스 | 폐섬유증 치료 또는 예방을 위한 세포 치료제 조성물 |
CN112121063B (zh) * | 2020-09-01 | 2022-04-29 | 北京诺德观呈医疗科技有限公司 | 外泌体在制备治疗肺纤维化的药物中的应用 |
CN114703130A (zh) * | 2022-03-28 | 2022-07-05 | 宁夏医科大学总医院 | 一种自体干细胞与卵泡液复合外泌体的制备方法及其应用 |
CN115025246B (zh) * | 2022-06-23 | 2024-04-30 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种双重靶向血管修复的多功能囊泡及其制备方法与应用 |
CN116077426B (zh) * | 2023-04-10 | 2023-06-27 | 北京大学第三医院(北京大学第三临床医学院) | 能够注射和缓释小分子化合物的外泌体靶向载药系统 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095749A1 (en) | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
US20070178073A1 (en) | 2006-02-01 | 2007-08-02 | Samsung Life Public Welfare Foundation | Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease |
EP2683389B1 (en) * | 2011-03-11 | 2017-05-03 | Children's Medical Center Corporation | Methods and compositions relating to mesenchymal stem cell exosomes |
EP2687219A1 (en) * | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
EP2956147B1 (en) * | 2013-02-12 | 2022-08-24 | Reneuron Limited | Method of producing microparticles |
GB201317887D0 (en) * | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product |
US9982233B2 (en) * | 2013-12-12 | 2018-05-29 | Samsung Life Public Welfare Foundation | Method for promoting generation of stem cell-derived exosome by using thrombin |
EP3145493B1 (en) * | 2014-05-18 | 2022-07-27 | Children's Medical Center Corporation | Methods and compositions relating to exosomes |
US20170232276A1 (en) * | 2014-09-30 | 2017-08-17 | Primegen Biotech, Llc | Treatment of fibrosis using deep tissue heating and stem cell therapy |
CN111773173B (zh) * | 2014-11-07 | 2024-03-22 | 胞外体干细胞株式会社 | 用于成脂分化诱导、脂肪组织再生、皮肤美白或改善皱纹的包含干细胞来源外泌体的组合物 |
WO2016072821A1 (ko) * | 2014-11-07 | 2016-05-12 | 한양대학교 에리카산학협력단 | 줄기세포 유래 엑소좀을 함유하는 지방세포 분화유도, 지방조직 재생, 피부 미백 또는 주름개선용 조성물 |
EP3223830A4 (en) * | 2014-11-24 | 2018-06-06 | Cytostormrx LLC | Encapsulated stem cells for the treatment of inflammatory disease |
EP3224348B1 (en) * | 2014-11-27 | 2021-07-14 | Med Cell Bahamas Ltd. | Secretomes and method for producing secretomes |
JP2017537630A (ja) * | 2014-12-03 | 2017-12-21 | カプリコール,インコーポレイテッド | 低酸素培養条件におけるエクソソームの生成方法 |
CN104666344B (zh) * | 2015-02-28 | 2019-09-20 | 广州医科大学附属第一医院 | 间充质干细胞外泌体在制备治疗肺纤维化的药物制剂中的应用 |
CN105296419A (zh) * | 2015-11-30 | 2016-02-03 | 华中科技大学同济医学院附属协和医院 | 促进皮肤创伤愈合的脂肪干细胞分泌的多因子载体exosome的制备及应用 |
-
2017
- 2017-08-03 JP JP2019506115A patent/JP6882450B2/ja active Active
- 2017-08-03 WO PCT/KR2017/008383 patent/WO2018026203A1/ko unknown
- 2017-08-03 EP EP17837254.6A patent/EP3494977A4/en not_active Withdrawn
- 2017-08-03 US US16/321,810 patent/US20210283183A1/en active Pending
- 2017-08-03 CN CN201780048940.XA patent/CN109562129B/zh active Active
- 2017-08-03 KR KR1020170098508A patent/KR101830290B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101830290B1 (ko) | 2018-02-21 |
WO2018026203A1 (ko) | 2018-02-08 |
EP3494977A4 (en) | 2020-03-18 |
EP3494977A1 (en) | 2019-06-12 |
KR20180016720A (ko) | 2018-02-19 |
JP2019527702A (ja) | 2019-10-03 |
CN109562129A (zh) | 2019-04-02 |
CN109562129B (zh) | 2023-02-17 |
US20210283183A1 (en) | 2021-09-16 |
KR101830290B9 (ko) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6882450B2 (ja) | 脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物 | |
KR102223374B1 (ko) | 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도 | |
JP6327647B2 (ja) | 炎症性疾患の予防又は治療用組成物 | |
JP6796143B2 (ja) | トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物 | |
JP6253590B2 (ja) | Hmgb1断片を利用した脊髄の損傷に対する新規治療法 | |
JP7473117B2 (ja) | 疼痛調節因子を含む幹細胞由来エクソソーム及びその用途 | |
Li et al. | Functional recovery after acute intravenous administration of human umbilical cord mesenchymal stem cells in rats with cerebral ischemia-reperfusion injury | |
CN113521101A (zh) | 干细胞来源的外泌体在制备治疗慢性阻塞性肺疾病药物中的应用 | |
AU2013259255B2 (en) | Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation | |
US20220249570A1 (en) | Nanovesicles from adult stem cells and its use for targeted therapy | |
Xue et al. | Curative effect and safety of intrathecal transplantation of neural stem cells for the treatment of cerebral hemorrhage | |
JP2021155335A (ja) | 変形性関節症の処置および/または予防方法 | |
KR20200132550A (ko) | 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 혈관질환 예방 또는 치료용 조성물 | |
WO2014141219A1 (en) | Umbilical cord blood derived stem cell transplantation for the treatment of neural disorder | |
KR102526447B1 (ko) | 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 간질환 예방 또는 치료용 조성물 | |
WO2022222987A1 (zh) | 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用 | |
JP2021107390A (ja) | 幹細胞の培養物を含む医薬の製造方法 | |
CN117778310A (zh) | 一种脐带间充质干细胞的制备方法及其应用 | |
JPS60149529A (ja) | 白血病細胞に対する分化誘導因子の産生方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210506 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6882450 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |